Dose-ranging study of riluzole in amyotrophic lateral sclerosis

Lancet

Volumn 347, Issue 9013, 1996, Pages 1425-1431

  Lacomblez, Lucette ^a   Bensimon, Gilbert ^a   Leigh, P Nigel ^b   Guillet, Philippe ^c   Meininger, Vincent ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LIVER ENZYME; RILUZOLE;

ABDOMINAL PAIN; ADULT; AMYOTROPHIC LATERAL SCLEROSIS; APNEA; ARTICLE; ASTHENIA; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FASCICULATION; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; LIVER DYSFUNCTION; MALAISE; MALE; MULTICENTER STUDY; MUSCLE CRAMP; MUSCLE STIFFNESS; MUSCLE STRENGTH; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PAIN; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FUNCTION; RESPIRATORY TRACT DISEASE; RISK BENEFIT ANALYSIS; SELF EVALUATION; SURVIVAL RATE; TRACHEOSTOMY; TREATMENT OUTCOME; VERTIGO;

EID: 0029977337     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)91680-3     Document Type: Article

References (25)

1. Rothstein JD. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Adv Neurol 1995; 68: 7-20.
2. Shaw PJ. Excitotoxicity and motor neuron disease: a review of the evidence. J Neurol Sci 1994; 124 (suppl): 1-13.
3. Meldrum B. Amino acids as dietary excitotoxins: a contribution to the understanding of neurodegenerative disorders. Brain Res Rev 1993; 18: 293-314.
4. Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol 1993; 250: 473-76.
5. Malgouris C, Daniel M, Doble A. Neuroprotective effects of riluzole on N-methyl-D-aspartate- or veratridine-induced neurotoxicity in rat hippocampal slices. Neurosci Lett 1994; 177: 95-99.
6. Couratier P, Sindou P, Esclaire F, Louvel E, Hugon J. Neuroprotective effects of riluzole in ALS CSF toxicity. Neuroreport 1994; 5: 1012-14.
7. Doble A, Hubert JP, Blanchard JC. Pertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on D-[3H]aspartate release from cultured cerebellar granule cells. Neurosci Lett 1992; 140: 251-54.
8. Debono M-W, Le Guern J, Canton T, Doble A, Pradier L. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed by Xenopus oocytes. Eur J Pharmacol 1993; 235: 283-89.
9. Hubert JP, Delumeau JC, Glowinski J, Promont J, Doble A. Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action. Br J Pharmacol 1994; 113: 261-67.
10. Bensimon G, Lacomblez L, Meininger V, ALS/Riluzole study group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585-91.
11. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994; 124 (suppl): 96-107.
12. Whitehead J. The design and analysis of sequential clinical trials, 2nd ed. New York: Ellis Horwood, 1992.
13. Peto R. Statistical aspects of cancer trials. In: Halman KE, ed. Treatment of cancer. London: Chapman & Hall, 1982: 868-71.
14. Tarone RE. Tests for trend in life table analysis. Biometrika 1975; 62: 679-82.
15. Wu MC, Carroll RJ. Estimation and comparison of changes in the presence of informative right censoring by modeling the censoring process. Biometrics 1988; 44: 175-88.
16. Norris F, Shepherd R, Denys E, et al. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci 1993; 118: 48-55.
17. Eisen A, Schulzer M, MacNeil M, Pant B, Mak E. Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve 1993; 16: 27-32.
18. Tysnes O-B, Vollset SE, Larsen JP, Aarli JA. Prognostic factors and survival in amyotrophic lateral sclerosis. Neuroepidemiology 1994; 13: 226-35.
19. Jablecki CK, Berry C, Leach J. Survival prediction in amyotrophic lateral sclerosis. Muscle Nerve 1989; 12: 833-41.
20. Kondo K, Hemmi I. Clinical statistic in 515 fatal cases of motor neuron disease. Neuroepidemiology 1984; 3: 129-48.
21. Kurtzke JF. Risk factors in amyotrophic lateral sclerosis. Adv Neurol 1991; 56: 245-70.
22. Woods JH, Koek W, France CP, Moerschbaecher M. In: Meldrum BS, ed. Excitatory amino acid antagonists. Oxford: Blackwell Scientific Publications, 1991: 237-64.
23. Hebert T, Drapeau P, Pradier L, Dunn RJ. Block of the rat brain IIA sodium channel a subunit by the neuroprotective drug riluzole. Mol Pharmacol 1994; 45: 1055-60.
24. Lingueglia E, Voilley N, Waldmann R, Lazdunski M, Barbry P. Expression cloning of an epithelial amiloride-sensitive Na+ channel: a new channel type with homologies to Caenorhabditis elegans degenerins. FEBS Lett 1993; 318: 95-99.
25. Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, Hall ED. Benefit of vitamin E, riluzole and gabapentin in a transgenic model of familial ALS. Ann Neurol 1995; 2: 147-57.